A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
The purpose of this study is to assess the effectiveness, safety, and actual treatment status of first-line nivolumab plus chemotherapy in participants with untreated advanced / recurrent gastric cancer in a Japanese real-world setting.
Stomach Neoplasms
Progression-free survival (PFS), Up to approximately 4 years|Objective response rate (ORR), Up to approximately 4 years|Incidence of all immune-related adverse events (irAE) according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0, Up to approximately 4 years|Incidence of treatment-related adverse events (TRAE) that have led to treatment discontinuation, Up to approximately 4 years
Overall survival (OS), Up to approximately 4 years|Duration of response (DOR), Up to approximately 4 years|Duration of treatment (DOT), Up to approximately 4 years|Time to next treatment (TNT), Up to approximately 4 years|Number of participants who have received subsequent therapy, Up to approximately 4 years|Incidence of Adverse Events (AEs), Up to approximately 4 years
The Time Perspective for this observational study is defined as 'Retrospective and Prospective'.